Similar articles

• Contemporary Hormonal Contraception and the Risk of Breast Cancer.

  Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Mørch LS, et al. N Engl J Med. 2017 Dec 7;377(23):2228-2239. doi: 10.1056/NEJMoa1700732. N Engl J Med. 2017. PMID: 29211679
• Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?

  Han L, Jensen JT. Han L, et al. Obstet Gynecol Clin North Am. 2015 Dec;42(4):683-98. doi: 10.1016/j.ogc.2015.07.007. Epub 2015 Sep 16. Obstet Gynecol Clin North Am. 2015. PMID: 26598309 Review.
• Risks of venous thromboembolism with various hormonal contraceptives.

  Allan GM, Koppula S. Allan GM, et al. Can Fam Physician. 2012 Oct;58(10):1097. Can Fam Physician. 2012. PMID: 23064919 Free PMC article. No abstract available.
• Oral oestrogen-progestagen contraceptives, menopausal treatment, and cancer.

  Shapiro S. Shapiro S. Lancet Oncol. 2005 Oct;6(10):736; author reply 737. doi: 10.1016/S1470-2045(05)70365-X. Lancet Oncol. 2005. PMID: 16198976 No abstract available.
• The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives.

  Shulman LP. Shulman LP. Am J Obstet Gynecol. 2011 Oct;205(4 Suppl):S9-13. doi: 10.1016/j.ajog.2011.06.057. Am J Obstet Gynecol. 2011. PMID: 21961825 Review.